Researchers looking for dementia in the eyes examine how they move, how the pupils respond to light, and what the retina reveals through advanced imaging. When a person develops cognitive decline or dementia, the brain areas controlling eye movement and pupil response degrade alongside memory and thinking, leaving measurable traces that show up in specialized eye tests before symptoms become obvious in behavior or cognition.
A patient with early-stage Alzheimer’s disease might have normal vision and no complaints about seeing, yet an eye-tracking test would show slower, less precise eye movements and difficulty following a moving target smoothly—patterns that correlate with the amount of neurodegeneration happening in the brain stem and midbrain regions controlling those movements. Unlike blood tests that measure specific protein markers, eye tests capture something more fundamental: how well the nervous system can coordinate rapid, precise movements and how the brain processes visual information. These tests are non-invasive, quick to administer, and do not require any contrast dyes or radiation, making them practical for older adults who may have other health conditions or medication complications.
Table of Contents
- What Changes Happen in Pupil Response as Dementia Develops?
- How Eye Movement Tracking Detects Cognitive Decline?
- What Do Retinal Images Reveal About Brain Health?
- How Are Eye Tests Currently Used to Screen for Dementia?
- What Are the Main Challenges in Using Eye Tests as Biomarkers?
- Combining Eye Data with Blood Biomarkers and MRI Findings
- What Happens During a Pupil Dilation Test and Why Dementia Patients Show Different Patterns?
What Changes Happen in Pupil Response as Dementia Develops?
The pupil—the dark center of the eye that opens and closes to control light entry—is controlled by an ancient part of the brain called the brainstem, the same region that handles basic survival functions like breathing and heart rate. When dementia begins, the pathological proteins spreading through the brain often damage these brainstem structures, and the pupil loses its quick reflexive response to light changes. In a healthy eye, the pupil constricts within a fraction of a second when bright light hits it; in someone with dementia, that response becomes sluggish, taking longer to react and failing to constrict as tightly as it should.
Researchers measure pupil size with infrared cameras and video pupillography, tracking how fast and how far the pupil shrinks when exposed to a sudden flash of light. Studies have found that people with Alzheimer’s disease show a significantly delayed pupil light reflex compared to cognitively normal older adults—a finding that holds up across different dementia types including Lewy body dementia and frontotemporal dementia. The limitation here is that while pupil sluggishness correlates with cognitive decline, it is not specific to dementia; Parkinson’s disease, certain medications, and even normal aging can slow pupil responses, so the test alone cannot diagnose dementia but rather adds to a larger clinical picture.
How Eye Movement Tracking Detects Cognitive Decline?
The eyes move in several distinct ways, each controlled by different brain regions and cognitive processes. Saccades are quick, voluntary jumps from one point to another—the kind of movement you make when reading a line of text or scanning a room. Smooth pursuit is the slow, fluid tracking motion you use to follow a moving object, like a bird flying across the sky. Vergence movements point both eyes inward or outward to maintain focus on objects at different distances.
Dementia degrades all three, but saccades often show the earliest and most pronounced changes. In eye-tracking studies, researchers ask participants to follow a dot moving on a screen or to look at targets appearing at different locations. People with mild cognitive impairment or early dementia produce saccades that are slower, more fragmented, and less accurate than healthy controls, often overshooting or undershooting the target. One study comparing eye-tracking patterns in Alzheimer’s disease found that patients took significantly longer to shift attention between visual targets and made more corrective movements, patterns that worsened as cognitive decline progressed. However, eye-tracking deficits are sensitive to many conditions beyond dementia—depression, anxiety, medication side effects, and even simple fatigue can impair saccadic speed and accuracy, which means abnormal eye movements point toward neurological changes but require clinical correlation to be interpreted correctly.
What Do Retinal Images Reveal About Brain Health?
The retina—the light-sensitive tissue lining the back of the eye—is an extension of the central nervous system, the only place in the body where brain tissue is directly visible without surgery. Optical coherence tomography (OCT), a non-invasive imaging technique using light waves to create detailed cross-sectional pictures of the retina, has revealed that people with Alzheimer’s disease often have thinning in the layer called the retinal nerve fiber layer (RNFL), the same layer affected in glaucoma but happening for a different reason. Instead of elevated eye pressure damaging the nerve fibers, neurodegeneration from dementia causes the nerve fibers in the retina to atrophy and die off.
Researchers at multiple centers have documented that RNFL thinning correlates with the severity of cognitive decline, with some studies finding that the thickness of the RNFL could distinguish between cognitively normal older adults and those with Alzheimer’s disease with moderate accuracy. A 2023 study following patients over several years found that baseline RNFL thickness predicted cognitive decline, suggesting the retinal changes may precede obvious symptoms. The practical advantage of retinal imaging is that it provides an objective, measurable anatomical change captured in a photograph, eliminating the subjectivity of behavioral testing. One significant limitation is that retinal thinning is slow and gradual, so a single snapshot of retinal thickness may not yet show a change in people very early in the disease process, and other retinal conditions like diabetic retinopathy or previous retinal detachment can confound the findings.
How Are Eye Tests Currently Used to Screen for Dementia?
Eye-based screening is not yet standard practice in most primary care or memory clinics, but a handful of specialized research centers and university hospitals are beginning to integrate eye testing into their cognitive assessment protocols. The process typically takes 20 to 45 minutes and involves multiple components: a pupil light reflex test, an eye-tracking task where the patient follows moving targets on a screen, retinal imaging with OCT or fundus photography, and sometimes additional tests like saccade latency measurements. The results are compared to normative databases of healthy controls matched by age and education, with the understanding that considerable variation exists among normal individuals.
One advantage of eye tests is their objectivity—a pupil response or retinal thickness measurement does not depend on the patient’s motivation, mood, or language ability, factors that can cloud results on cognitive testing in older adults with depression or hearing loss. A comparison illustrates the point: a patient with severe depression might perform poorly on memory testing simply because they lack motivation and interest, yet their eye movements and retinal imaging would reflect only the neurological reality. The trade-off is that eye tests require expensive equipment, trained technicians, and standardized protocols, making them impractical for community health centers or primary care offices where most older adults are screened for cognitive problems.
What Are the Main Challenges in Using Eye Tests as Biomarkers?
The biggest barrier to widespread adoption of eye-based dementia screening is the problem of overlap: abnormal eye test results occur in many non-dementia conditions, and normal eye test results do not rule out dementia. Parkinson’s disease produces eye-movement abnormalities that can mimic those seen in dementia. Diabetic retinopathy causes retinal changes that might obscure the subtle RNFL thinning associated with Alzheimer’s. Depression and anxiety affect pupil responses and eye-tracking accuracy.
A patient taking certain antihistamines or antipsychotics might have delayed pupil responses unrelated to cognition. This means that while eye tests may eventually help identify people at risk for dementia, they cannot stand alone as a diagnostic tool and must always be interpreted alongside cognitive testing, imaging, and clinical history. Another significant challenge is standardization. Different research groups use different eye-tracking systems, different imaging protocols, and different cut-off values for what counts as “abnormal,” making it difficult to compare results across studies or apply research findings to clinical practice. The field would benefit from large, well-designed prospective studies following thousands of cognitively normal older adults over many years, measuring their eye parameters at baseline and then tracking who develops cognitive decline, but such studies require substantial funding and take a decade or more to complete.
Combining Eye Data with Blood Biomarkers and MRI Findings
The future of dementia detection likely involves combining information from multiple sources rather than relying on any single test. Eye movements correlate with tau and amyloid pathology measured in blood tests, and retinal thinning aligns with brain atrophy seen on MRI scans, suggesting that eye changes reflect the same underlying neuropathology affecting the brain.
A patient might have a blood test showing elevated phosphorylated tau (suggesting Alzheimer’s pathology), an MRI showing hippocampal atrophy (indicating memory-center shrinkage), delayed pupil responses (showing brainstem involvement), and RNFL thinning (reflecting retinal neurodegeneration)—each test adding a piece of evidence that together create a much more convincing case for early cognitive changes than any single test alone. Some research teams are now building machine-learning algorithms that combine eye-tracking data, retinal measurements, cognitive test scores, and blood biomarkers into a single prediction model. Early results suggest that multimodal approaches can identify people at high risk for future cognitive decline with better accuracy than any test used in isolation, opening the possibility that eye tests might become a practical, non-invasive screening tool once the algorithms are refined and validated across diverse patient populations.
What Happens During a Pupil Dilation Test and Why Dementia Patients Show Different Patterns?
During a standard pupil dilation test used in eye clinics, eye care professionals place dilating drops into the eyes and wait about 20 to 30 minutes for the pupils to open wide, allowing them to see the retina clearly through an ophthalmoscope or retinal camera. In people with dementia, research has shown that the dilation process itself may proceed more slowly, and once dilated, the pupils may not hold the dilated state as steadily as in healthy older adults, sometimes fluctuating in size even under constant lighting.
The explanation lies in the neurochemical systems controlling pupil size: dementia pathology often damages nerve cells that produce acetylcholine and other neurotransmitters regulating pupil muscles, so the pupil’s response to both the dilating medication and to light becomes erratic. A practical observation from dementia clinics is that patients sometimes report increased sensitivity to bright light after dilation, experiencing discomfort or difficulty in well-lit waiting rooms, a symptom more pronounced in those with advanced cognitive decline. This heightened light sensitivity, combined with the slower pupil response measured objectively, suggests that dementia affects not just the mechanical pupil response but also the brain’s interpretation of visual brightness, implicating changes in the thalamus and visual cortex alongside brainstem changes.
